Cat. #151090


Cat. #: 151090

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Epidermal Growth Factor Receptor (EGFR, Her1)

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Peter Goodfellow

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Related Tools

Tool Details


  • Name: Anti-EGFR [EGFR1]
  • Alternate name: CCNA1; Cyclin A1; Testicular Tissue Protein Li 34; CT146
  • Clone: EGFR1
  • Tool type ecom: Antibodies
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 175 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: Monoclonal antibody which binds EGFR1 tyrosine kinase, commonly mutated in a range of cancers.
  • Immunogen: Human epidermoid carcinoma line A431
  • Immunogen uniprot id: P00533
  • Isotype: IgG2b kappa
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Epidermal Growth Factor Receptor (EGFR, Her1)
  • Molecular weight: 175 kDa
  • Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on EGFR signalling to maintain their malignant phenotypes.


  • Application: FACS ; IHC ; IF ; IP ; WB


  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

Related Tools

  • Related tools: Anti-EGFR, Recombinant [EGFR1]


  • Finetti et al. 2015. Endocr Relat Cancer. 22(4):665-78. PMID: 26113609.
  • Perillo et al. 2015. Nat Commun. 6:7874. PMID: 26219252.
  • Tang et al. 2015. Oncol Rep. 34(1):350-8. PMID: 25955689.
  • mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
  • Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface.
  • Boersma et al. 2011. J Biol Chem. 286(48):41273-85. PMID: 21979953.
  • Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
  • Jensen et al. 2006. Proc Natl Acad Sci U S A. 103(32):11958-63. PMID: 16877544.
  • Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.
  • Gullick et al. 1986. Cancer Res. 46(1):285-92. PMID: 2998607.
  • Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas.
  • Waterfield et al. 1982. J Cell Biochem. 20(2):149-61. PMID: 6188757.
  • A monoclonal antibody to the human epidermal growth factor receptor.